- Oops!Something went wrong.Please try again later.
Surrey, British Columbia --News Direct-- Izotropic Corporation
VANCOUVER, BC - TheNewswire - October 26, 2021 - Izotropic Corporation (“Izotropic” or the “Company”) (CNSX:IZO.CN) (OTC:IZOZF) (FSE:1R3), a Company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers is pleased to announce the results of its Annual General Meeting held via teleconference on October 2, 2021.
Company matters submitted to shareholders for approval as set out in the Company's Notice of Meeting and Management Information Circular, both dated September 8, 2021, were approved by a vote of 29.52% of issued and outstanding shares, the requisite majority of votes cast at the meeting.
The approvals included the following:
Election of Directors:
Robert Thast John Boone Ali Sodagar Ralph Proceviat
Appointment of Auditor:
Dale Matheson Carr-Hilton LaBonte LLP
The Company wishes to thank Mr. Marshall Severyn for his contributions to Izotropic and his service to the company as a Director and Vice President of Marketing. Dr. John McGraw, the Company’s current Chief Executive Officer, has been elected to the Board of Directors.
ON BEHALF OF THE BOARDDr. John McGraw, CEO
For investor relations inquiries, contact:James BerardEmail: email@example.comCell: 778-228-2314Toll Free: 1-833-IZOCORP ext.1
About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic’s initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures and will initiate in Q2 2022. In follow-on clinical studies, Izotropic intends to validate platform applications including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the Company’s management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company’s activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind.
View source version on newsdirect.com: https://newsdirect.com/news/izotropic-announces-2021-agm-results-703621860